GILD vs PTGX · P/E 18, rev $7.80B vs rev $269.8M
Gilead Sciences Inc (GILD) versus Protagonist Therapeutics Inc (PTGX) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US. It is led by Daniel P. O'Day.
Protagonist Therapeutics Inc (PTGX) is a biotechnology company listed on NASDAQ.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Latest reported PTGX revenue for 2026-06-30 was $269.8M. Net income was $166.6M. PTGX currently screens at market cap $7.25B.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. PTGX currently screens at market cap $7.25B.
Not investment advice. Open the GILD and PTGX stock pages for the full models.
Not investment advice.